Nevertheless, looking at more advanced patients, with CD4 counts up to 200 cells/mm3 or AIDS, LPV/r including regimens resulted to be at lower risk of virological failure as in the multivariate model, ATV/r showed a 3.7-fold statistically significant higher risk and DRV/r a 3.1-fold not significant higher risk. The gene discussed is CD4; the disease is AIDS.